Zenith Epigenetics Announces Start of Several National
Seven NCI sponsored trials will evaluate safety and efficacy of its BET inhibitor (BETi) ZEN-3694 in combination with several targeted agents and/or...
Source: globenewswire.com
📰 Combination With News
Page 4 - Combination With News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Combination With. Real-time updates on events, politics, business and more.
Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the Phase 1 MonumenTAL-1 first-in-human...
Source: prnewswire.com
AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses
/PRNewswire/ -- AbbVie (NYSE: ABBV) will present 46 abstracts across eight types of cancer during the upcoming American Society of Clinical Oncology (ASCO)...
Source: prnewswire.com
Investegate |NetScientific PLC Announcements | NetScientific PLC: PDS Phase 2 Trial Update
Investegate announcements from NetScientific PLC, PDS Phase 2 Trial Update
Source: investegate.co.uk
NewsNow: Cystic Fibrosis news | Breaking News & Search 24/7
Breaking news headlines about Cystic Fibrosis, linking to 1,000s of sources around the world, on NewsNow: the one-stop shop for breaking news
Source: newsnow.co.uk
New Clinical and Real-World Data Support Use of DARZALEX® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new analyses illustrating responses that first-line treatment with...
United States Bortezomib Melphalan Velcade Melphalan Jacob Laubach Velcade Bortezomib Melphalan Jessica Moore
Source: prnewswire.com
New Clinical and Real-World Data Support Use of DARZALEX® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new analyses illustrating responses that first-line treatment with...
United States Bortezomib Melphalan Velcade Melphalan Jacob Laubach Velcade Bortezomib Melphalan Jessica Moore
Source: prnewswire.com
Cardiology Information Systems Overview in 2021
KLAS report says there is opportunity for market disruption
Monique Rasband Sam Eaquinto Emily Paxman Epic Cupid Is Largely Limited To Scheduling Watson Health Ge Healthcare
Source: dicardiology.com
Alkermes to Present New Research From Psychiatry and Addiction Portfolios at Upcoming Scientific Conferences
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present research from its psychiatry and addiction portfolios at upcoming scientific...
Source: prnewswire.com
Servier gibt positive Topline-Daten aus der internationalen Phase-3-Studie mit TIBSOVO (Ivosidenib-Tabletten) in Kombination mit Azacitidin bei Patienten mit zuvor unbehandelter akuter myeloischer Leukämie mit IDH1-Mutationen bekannt
Servier gibt positive Topline-Daten aus der internationalen Phase-3-Studie mit TIBSOVO (Ivosidenib-Tabletten) in Kombination mit Azacitidin bei Patienten mit zuvor unbehandelter akuter myeloischer Leukämie mit IDH1-Mutationen bekannt Das Sicherheitsprofil entspricht den zuvor veröffentlichten Daten bei Patienten mit akuter myeloischer Leukämie mit IDH1-Mutationen. Aufgrund der überzeugenden Ansprechdaten von TIBSOVO wurde die weitere Aufnahme in die Studie vor kurzem eingestellt. Servier,...
Source: finanznachrichten.de